This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Edwards Lifesciences (EW) Gains on Innovation, Margin Growth
by Zacks Equity Research
In Edwards Lifesciences' (EW) Smart Recovery portfolio, the adoption of FloTrac and ClearSight sensors remains strong.
AMN Healthcare (AMN) Q4 Earnings, Revenues Beat Estimates
by Zacks Equity Research
Despite AMN Healthcare's (AMN) robust results in the majority of its segments, it records a soft overall Q4 performance.
Here's Why You Should Retain Inari Medical (NARI) Stock Now
by Zacks Equity Research
Inari Medical (NARI) continues benefiting from its commitment to understand the venous system. However, dependency on the wide adoption of products is a concern.
AMN Healthcare Services (AMN) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare (AMN) delivered earnings and revenue surprises of 14.29% and 5.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain OPKO Health (OPK) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in RAYALDEE.
Boston Scientific (BSX) Gains From New Buyouts, Cost Woes Stay
by Zacks Equity Research
Boston Scientific's (BSX) EMEA business grows above market, supported by the company's ongoing investments in emerging markets.
Here's Why You Should Add Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to boost the top line further.
Quest Diagnostics (DGX) New Pact to Boost Laboratory Services
by Zacks Equity Research
Quest Diagnostics' (DGX) recent agreement is intended to offer advanced and quality clinical laboratory services in the greater New York region and beyond.
Reasons Why You Should Retain ResMed (RMD) Stock For Now
by Zacks Equity Research
Investors are optimistic about ResMed (RMD) owing to the increased demand for its sleep and respiratory care devices.
Medical Device Stocks' Q4 Earnings on Feb 16: WST, SWAV & More
by Indrajit Bandyopadhyay
Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat macro headwinds. Let's see how WST, SWAV, AMN, ITGR and PACB are likely to fare this time.
McKesson (MCK) Announces Availability of FDA-Cleared Drug for MCL
by Zacks Equity Research
The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for MCL.
Thermo Fisher (TMO) Rides on Strong End Markets, New Launches
by Zacks Equity Research
Thermo Fisher's (TMO) newly-launched Gibco CTS DynaCellect Magnetic Separation System is helping customers advance their cell and gene therapy programs.
Charles River (CRL) Introduces Novel IgY-Based ELISA Kit
by Zacks Equity Research
Charles River's (CRL) HCP-ELISA is built on its HCP-GAPex service, enhancing the efficiency and efficacy of HCP assay development.
ResMed's (RMD) Mask Sales Drive Growth, Margin Issue Lingers
by Zacks Equity Research
ResMed (RMD) continues to see robust demand for its market-leading mask portfolio despite being faced with challenges related to lower new patient setups from a competitor recall.
Here's Why You Should Retain Walgreens Boots (WBA) For Now
by Zacks Equity Research
Investors are optimistic about Walgreens Boots (WBA) on continued partnership growth and a strong focus on strategic execution.
Abbott (ABT) to Expand Vascular Device Line With New Buyout
by Zacks Equity Research
Abbott's (ABT) latest deal will help gain access to Cardiovascular System's leading atherectomy device to treat vascular disease.
AMN Healthcare (AMN) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
AMN Healthcare's (AMN) fourth-quarter results are likely to reflect soft demand across the majority of its segments.
Abbott (ABT) EPD Growth Continues Amid Macroeconomic Challenges
by Zacks Equity Research
At Abbott (ABT), Medical Device sales growth is led by strong performance in Electrophysiology, Structural Heart and Diabetes Care.
BD's (BDX) Latest Combination Test Receives the FDA's EUA
by Zacks Equity Research
BD's (BDX) new combination test is likely to significantly aid clinicians in treating patients in the current and future respiratory virus seasons.
AMN Healthcare Services (AMN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
AMN Healthcare Services (AMN) closed the most recent trading day at $93.60, moving -1.84% from the previous trading session.
3 Reasons to Retain NextGen (NXGN) Stock in Your Portfolio
by Zacks Equity Research
NextGen's (NXGN) strong product portfolio and continued demand for its solutions raise optimism about the stock.
Should SPDR S&P 600 Small Cap ETF (SLY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SLY
LabCorp's (LH) New Launches, Planned Spinoff to Aid Growth
by Zacks Equity Research
In terms of portfolio enhancement, LabCorp (LH) enters into a collaboration with Becton, Dickinson and Company to advance in life-changing treatments for cancer and other diseases.
AMN or DOCS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMN vs. DOCS: Which Stock Is the Better Value Option?
Is AMN Healthcare Services (AMN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how AMN Healthcare Services (AMN) and Sorrento Therapeutics (SRNE) have performed compared to their sector so far this year.